The DROP-IN gamma probe technology developed at the LUMC has received CE certification. This means that hospitals throughout Europe can use the device. The probe improves the detection of tumors during operation procedures with a surgical robot. The technology is currently being commercialized by Crystal Photonics. What started off as an internship project has turned into a product that has reached the market. What did this process look like?
Matthias van Oosterom, a postdoc in the Department of Radiology, began his internship at the LUMC in 2014 with the Interventional Molecular Imaging group. His project entailed developing a device that would enable better detection of prostate tumors during image-guided surgery. “During image-guided operations, such as radio-guided surgery, patients are first administered a tracer that goes into the tumor. With a probe that detects the tracer, the surgeon know when the tracer is near the tumor, allowing the precise removal of tumor tissue”, explains Van Oosterom.
The Janssen-Cilag International N.V COVID-19 vaccine has received authorization for emergency use by the European Medicines Agency (EMA) on March 11. Developed with fundamental support from the Molecular Virology group of the Leiden University Medical Centre (LUMC), it is the fourth vaccine to be administered in the European Union. The Netherlands has ordered more than 11 million vaccine doses.
For many students from the LUMC’s academic programmes, studying abroad is an indispensable experience. Doing part of your studies abroad is a special experience, not only because of the sense of adventure of being abroad, also to develop a broader perspective on Life Sciences & Health, a highly international field. So, you can imagine the LUMC’s International Office’s struggle to have to tell students ‘no’ for a study experience abroad in the midst of the corona pandemic. In addition, the many lockdowns worldwide increased the workload dramatically for the International Office. Evelien Hack, Head of the International Office and Sandra van Deursen, senior administrative assistant, share how corona has impacted studying abroad.
The Leiden University Medical Center (LUMC) and Ixaka Ltd. have announced a research collaboration on 30 March 2021, to better understand REX-001, Ixaka’s lead cell therapy product. The project will be led by Professor Paul Quax, Head of Experimental Vascular Surgery at the LUMC, to support accelerated development of REX-001 in Phase III clinical trials for the treatment of chronic limb-threatening ischemia (CLTI).